Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azoxymethane
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Subcutaneous
01
Overview
Azoxymethane is a potent carcinogenic and neurotoxic small molecule used primarily in biological research. It is the oxide of azomethane and is particularly effective at inducing colon carcinoma in laboratory animals, especially rodents. Azoxymethane acts as a DNA-damaging agent by inducing O6-methylguanine adducts in DNA, leading to G→A transitions and subsequent tumorigenesis. It is widely used to create animal models for studying the mechanisms of colon cancer progression and chemoprevention strategies[1][2][4][5][8]. Azoxymethane is not approved for human use; it serves exclusively as a research tool.
- Other names
- azoxymethaneDiazene, dimethyl-, 1-oxidemethane, azoxy-CCRIS 67CCRIS67CCRIS-67
02
Targets
DNA
Beyond the preview
Go deeper on azoxymethane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azoxymethane.